LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

Home・Akciju saraksts・Merck & Co Inc.

Merck & Co Inc.

Slēgts

SektorsVeselības aprūpe

113.2 0.05

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

112.83

Max

114.04

Galvenie mērījumi
By Trading Economics
Ienākumi	-7.2B -4.2B
Pārdošana	-114M 16B
P/E Sektora vidējais	31.507 49.8
EPS	-1.28
Dividenžu ienesīgums	2.92
Peļņas marža	-26.053
Darbinieki	73,000
EBITDA	-6.2B -1.9B

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+20.87% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	2.92% 2.25%
Nākamais dividenžu datums	2026. g. 7. jūl.
Nākamais Ex dividenžu datums	2026. g. 15. jūn.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	7.1B 279B
Iepriekšējā atvēršanas cena	113.15
Iepriekšējā slēgšanas cena	113.2

Ziņu noskaņojums

By Acuity

23%

77%

76 / 347 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

76.03 / 83.28 Atbalsts un pretestība

Merck & Co Inc. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 30. apr. 14:20 UTC

Peļņas

Merck 1Q Sales Rise on Continued Keytruda Growth -- Update

2026. g. 30. apr. 10:45 UTC

Peļņas

Merck 1Q Sales Rise on Continued Keytruda Growth

2026. g. 5. maijs 18:12 UTC

Peļņas

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

2026. g. 5. maijs 13:54 UTC

Peļņas

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

2026. g. 5. maijs 12:48 UTC

Iegādes, apvienošanās, pārņemšana

Merck Cites Costs Associated With Advancing TERN-701 and Financing >MRK

2026. g. 5. maijs 12:48 UTC

Iegādes, apvienošanās, pārņemšana

Merck: GAAP and Adj EPS Expected to Be Negatively Impacted by About 12c/Shr in 2026 >MRK

2026. g. 5. maijs 12:47 UTC

Iegādes, apvienošanās, pārņemšana

Merck: Transaction Expected to Be Accounted for as Asset Acquisition, Resulting in Chg of About $5.8 B, or $2.35/Shr, Included in 2Q and FY26 Results >MRK

2026. g. 5. maijs 12:45 UTC

Iegādes, apvienošanās, pārņemšana

Merck Completes Acquisition Of Terns Pharmaceuticals, Inc. >MRK TERN

2026. g. 1. maijs 18:35 UTC

Peļņas

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

2026. g. 1. maijs 14:53 UTC

Peļņas

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

2026. g. 30. apr. 13:27 UTC

Peļņas

Merck Stock Falls After Earnings. It's Working on Ways to Blunt Future Lost Keytruda Sales. -- Barrons.com

2026. g. 30. apr. 10:47 UTC

Peļņas

Update: Merck Stock Rises on Earnings. These Problems Loom Larger Than Keytruda Patent Cliff. -- Barrons.com

2026. g. 30. apr. 10:30 UTC

Peļņas

Merck: Also Anticipate EPS Will Be Negatively Affected by About 12c Over Remainder of 2026 Following Close of Terns Deal >MRK

2026. g. 30. apr. 10:30 UTC

Peļņas

Merck Raises 2026 View To Adj EPS $5.04-Adj EPS $5.16 Vs Prior View $5-$5.15 >MRK

2026. g. 30. apr. 10:30 UTC

Peļņas

Merck: 2026 Outlook Doesn't Reflect Any Impact From Proposed Acquisition of Terns Pharmaceuticals, Which Is Expected to Close in May and Result in One-Time Charge of About $2.35/Shr >MRK

2026. g. 30. apr. 10:30 UTC

Peļņas

Merck: Sales Outlook Includes Positive Impact From Forex of About 1% at Mid-April 2026 Exchange Rates >MRK

2026. g. 30. apr. 10:30 UTC

Peļņas

Merck: Adj EPS Outlook Also Reflects One-Time Charge of $3.62/Shr for Acquisition of Cidara >MRK

2026. g. 30. apr. 10:30 UTC

Peļņas

Merck: Adj EPS Outlook Includes Positive Impact From Forex of About 10c/Shr at Mid-April 2026 Exchange Rates >MRK

2026. g. 30. apr. 10:30 UTC

Peļņas

Merck Narrows 2026 View To Sales $65.8B-$67B Vs Prior View $65.5B-$67B >MRK

2026. g. 30. apr. 10:30 UTC

Peļņas

Merck: Latest 1Q Includes Charge of $3.62/Share for the Acquisition of Cidara >MRK

2026. g. 30. apr. 10:30 UTC

Peļņas

Merck: 1Q Gardasil/Gardasil 9 Sales Also Reflect Lower Sales in U.S. Primarily Due to Unfavorable Public-Sector Purchasing Patterns, Partially Offset by Higher Net Pricing >MRK

2026. g. 30. apr. 10:30 UTC

Peļņas

Merck 1Q Gardasil/Gardasil 9 Sales Down 19% >MRK

2026. g. 30. apr. 10:30 UTC

Peļņas

Merck: Lower 1Q Januvia/Janumet Sales Due to Lower Demand and Net Pricing in U.S., Lower Demand in China and Most Other International Markets Due to Generic Competition >MRK

2026. g. 30. apr. 10:30 UTC

Peļņas

Merck: Pleased With Progress and Excited for What's Ahead, as We Enter Particularly Robust Period of Phase 3 Data Readouts and Deliver on Promise of Our Pipeline for Patients >MRK

2026. g. 30. apr. 10:30 UTC

Peļņas

Merck 1Q Winrevair Sales $525M, Up 88%, Reflecting Continued Uptake in U.S. and Early Launch Uptake in Certain Intl Mkts, Especially Japan and Europe >MRK

2026. g. 30. apr. 10:30 UTC

Peļņas

Merck: 1Q Animal Health Sales Growth Attributable to Performance in Both Livestock and Companion Animal Product Portfolios >MRK

2026. g. 30. apr. 10:30 UTC

Peļņas

Merck: Lower 1Q Gardasil/Gardasil 9 Sales Primarily Due to Lower Demand in China as Well as Lower Sales in Japan Following National Catch-Up Immunization Program >MRK

2026. g. 30. apr. 10:30 UTC

Peļņas

Merck 1Q Pharmaceutical Sales Up 5% >MRK

2026. g. 30. apr. 10:30 UTC

Peļņas

Merck 1Q Animal Health Sales Up 13% >MRK

2026. g. 30. apr. 10:30 UTC

Peļņas

Merck 1Q Sales $16.29B >MRK

Salīdzinājums

Cenas izmaiņa

Merck & Co Inc. Prognoze

Cenas mērķis

By TipRanks

20.87% augšup

Prognoze 12 mēnešiem

Vidējais 136.72 USD 20.87%

Augstākais 179 USD

Zemākais 112 USD

Pamatojoties uz 20 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Merck & Co Inc. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

20 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 20 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Merck & Co Inc. — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

76.03 / 83.28Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Noskaņojums

By Acuity

76 / 347 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.